Targeted therapy in advanced bladder cancer: What have we learned? Journal Article
| Authors: | Jordan, E. J.; Iyer, G. |
| Article Title: | Targeted therapy in advanced bladder cancer: What have we learned? |
| Abstract: | Despite advances in the treatment of other genitourinary malignancies, no novel therapies have been approved by the US Food and Drug Administration for urothelial carcinoma (UC) in the last 20 years. To date, no clinical trials of targeted agents in UC have led to improvements in survival compared with cytotoxic therapy. This article outlines representative trials of targeted therapies in UC and discusses the significance of genetic preselection in trial design as a method to optimize responses to these agents, thus, hopefully expanding the armamentarium of treatment options against this lethal disease. © 2015 Elsevier Inc. |
| Keywords: | angiogenesis; urothelial carcinoma; targeted therapy; small molecule inhibitors; mapk pathway; pi3k/akt/mtor pathway; next-generation sequencing |
| Journal Title: | Urologic Clinics of North America |
| Volume: | 42 |
| Issue: | 2 |
| ISSN: | 0094-0143 |
| Publisher: | W.B. Saunders Co-Elsevier Inc. |
| Date Published: | 2015-05-01 |
| Start Page: | 253 |
| End Page: | 262 |
| Language: | English |
| DOI: | 10.1016/j.ucl.2015.01.006 |
| PROVIDER: | scopus |
| PUBMED: | 25882566 |
| PMCID: | PMC4939834 |
| DOI/URL: | |
| Notes: | Article -- Export Date: 3 February 2016 -- Source: Scopus |
Altmetric
Citation Impact
BMJ Impact Analytics
Related MSK Work